HUTCHMED climbs 4.1% as AstraZeneca seeks US approval for cancer drug combo
Shares rose to HK$23.1, the highest since September 4, and were on track for their biggest one-day gain since September 21.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.